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clone ultimately responsible for clinical relapse; further
work will be needed to determine if this will be a signiﬁcant
factor requiring modiﬁcation of the bioinformatics strategy
employed in post allo-SCT monitoring.
The prognostic signiﬁcance of MRD in patients with
ALL undergoing SCT had previously been established [15]
and the use of MRD-guided therapy has already resulted in
remarkable outcomes in the treatment of children with ALL
[16]. The advance, therefore, represented by this NGS
approach is the ability to have a standardized, extremely
sensitive MRD platform available for most cases of ALL. This
should allow the truly “next generation” era of MRD to be
reached; the use of highly sensitive measurement of dis-
ease burden to routinely determine treatment efﬁcacy and
make evidence-based clinical decisions, in real-time, re-
garding the most appropriate next therapeutic intervention
for an individual patient. Risk stratiﬁcation based not on
historical, population-average correlates of the likely disease
biology and chemo-sensitivity of the predominant leukemic
clone before any treatment, but rather on the actual amount
of malignant disease a patient still has left requiring treat-
ment at key clinical decision points “moves the goal posts”
and will allow true personalization of therapy.
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Accepted 5 July 2014The only potentially curative treatment for patients with
myelodysplastic syndrome (MDS) is allogeneic hematopoietic
stem cell transplantation (allo-HSCT). However, the effec-
tiveness of this approach is limited by considerable morbidity
and mortality. The introduction of reduced-intensity condi-
tioning regimens has resulted in a signiﬁcant reduction in
transplantation-related mortality, leading to a rapidly
growing number of transplantations in elderly patients.
Despite these recent advances, the long-term survival
rate is currently about 30% [1]. In MDS patients receiving
reduced-intensity conditioning, disease relapse represents
the leading cause of transplantation failure, especially in
those with an advanced disease stage (ie, intermediate-2
and high International Prognostic Scoring System risk). The
M.G. Della Porta & E.P. Alessandrino / Biol Blood Marrow Transplant 20 (2014) 1259e1261 1261issue of performing cytoreductive chemotherapy before
allo-HSCT in these patients to reduce the risk of disease
relapse is a matter of debate. Signiﬁcant concerns about
chemotherapy, such as that used to treat acute myeloid
leukemia, include the low response rate and the risk of long-
lasting myelosuppression and organ toxicities. It should be
considered, in addition, that there is no deﬁnitive evidence
of a survival beneﬁt associated with administering chemo-
therapy before allo-HSCT in patients with MDS [1,2]. The
only randomized study, from the European Group for Blood
and Marrow Transplantation, had to be stopped because of
slow recruitment, whereas retrospective single-center
studies showed no conclusive results, with additional se-
lection bias as a result of the impossibility of accounting for
patient drop-out (ie, patients who received induction
chemotherapy but never received allo-HSCT because of
death or toxicity) [2].
The availability of hypomethylating agents, including
5-azacitidine and decitabine, has changed the landscape of
MDS treatment. Azacitidine results in hematologic im-
provements in approximately 25% to 50% of cases and com-
plete response in 10% to 20%, with prolonged survival,
compared with supportive care alone in high-risk MDS, with
a good toxicity proﬁle, compared with induction chemo-
therapy [3].
Although hypomethylating agents can induce hemato-
logical and cytogenetic responses, these therapies do not
appear to eradicate MDS clones, and recent data suggest that
even in patients ages 60 to 70 years and with intermediate-2
or high international prognostic scoring system risk, trans-
plantation offers a survival beneﬁt with respect to non-
transplantation procedures [4]. The use of hypomethylating
agents is, therefore, increasing as a bridge to more deﬁnitive
therapy, as a part of a comprehensive strategy to prevent
relapse after allo-HSCT in MDS patients with advanced dis-
ease. The mechanism by which hypomethylating agents
exert an antitumor effect in MDS remains not completely
understood. Inhibition of DNA methyltransferases results in
hypomethylation and, consequently, might result in reac-
tivation of tumor suppressor genes, terminal differentiation,
and apoptosis of neoplastic cells, with reduction of tumor
burden before allo-HSCT. In addition, treatment with hypo-
methylating agents seems to affect T cellemediated and
innate immunity.
Several studies have evaluated the role of hypo-
methylating agents given before transplantation, although
very few were conducted prospectively. Overall, these in-
vestigations showed similar post-transplantation outcomes
for patients receiving hypomethylating agents versus those
receiving remission-induction chemotherapy, without sig-
niﬁcant treatment-related toxicity. Moreover, in some cases,
an improved outcome was reported for patients who un-
derwent transplantation in complete remission compared
with those with active disease at the time of allo-HSCT [5,6].
In the present issue of Biology of Blood and Marrow
Transplantation, Damaj et al. examined the impact of pre-
transplantation treatment with azacitidine in 128 consecu-
tive MDS patients who received reduced-intensity or
nonmyeloablative conditioning allo-HSCT. In this series,patients with MDS who underwent upfront allo-HSCT
without prior cytoreduction had similar outcomes
compared with those who received azacitidine as a pre-
conditioning treatment, in terms of overall survival and cu-
mulative incidence of relapse and nonrelapse mortality,
emphasizing the need to perform prospective protocols to
delineate the role of a debulking strategy and to identify
subsets of patients who may beneﬁt from this approach. In
the absence of data from prospective trials on patients with
MDS who are candidates for allo-HSCT, the decision to
perform a cytoreductive treatment should be made on an
individual basis, accounting for clinical considerations with
respect to each speciﬁc patient. As the rate of complete
remission is generally higher with induction chemotherapy
compared with the rate for hypomethylating agents, that
strategy might still be the best option in selected medically
ﬁt patients with immediate availability of a suitable donor.
On the other hand, hypomethylating agents could be
considered mainly for older patients (including those with
comorbidity) who are at risk of losing eligibility for a trans-
plantation procedure as a result of treatment-related toxicity
and as a bridging strategy to allo-HSCT in subjects where no
donor has yet been identiﬁed. Finally, azacitidine and deci-
tabine may be active in patients with a complex karyotype,
for whom conventional chemotherapy invariably fails.ACKNOWLEDGMENTS
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